Nuvisertib, an oral PIM1 kinase inhibitor from Sumitomo Pharma, has received Orphan Drug Designation from the EMA for ...

A new study published in Cancer Cell reveals that blocking a key nutrient-scavenging process in pancreatic tumors reprograms the tumor microenvironment—reducing fibrosis, enhancing T cell infiltration ...

Antibody-drug conjugates and bispecific antibodies are reshaping the future of targeted therapy in oncology and immunology.

In this exclusive interview, Dr. Raza Bokhari, CEO of Medicus Pharma, introduces SkinJect patch—a cellulose-based microneedle ...

In a breakthrough study published in Science, researchers unveiled an AI-driven platform capable of designing precision ...

The FDA granted Priority Review and Breakthrough Therapy Designation to Imfinzi for resectable gastric and GEJ cancers, based ...

A team of international scientists has uncovered a novel way to boost the cancer-killing power of the immune system’s T cells—by flipping a metabolic switch deep within their mitochondria.

Macrophage checkpoint inhibitors promise a transformative role in cancer immunotherapy; by targeting the “don’t eat me” ...

The START Center for Cancer Research has announced a strategic partnership with Advarra to accelerate and streamline early-phase oncology trials across its global network. By integrating Advarra’s ...

The growing incidence of HPV16-positive cancers represents a significant challenge in oncology despite recent therapeutic advances. In this exclusive interview, Frank Bedu-Addo, President and CEO of ...

The American Cancer Society (ACS) and its advocacy arm, the American Cancer Society Cancer Action Network (ACS CAN), have appointed Shane Jacobson as their new Chief Executive Officer, effective ...